Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
The kit is developed for quantitative detection of natural and recombinant human IL-8 in serum, plasma and cell culture supernatants.
It is for research use only.
Assay Type | Sandwich-ELISA |
Analyte | IL-8 |
Format | 96-wells plate breakable into 12 x 8 wells strips |
Reactivity | Human |
Sensitivity | 3.0 pg/mL |
Assay Time | 1.75 hr |
Sample volume | 50 uL |
Range | 6.25 pg/mL-400 pg/mL |
Sample Type | Cell Culture Supernatants, Plasma, Serum. |
NIBSC Code | 89/520 |
Elevate your research experience with our Cytokine/Biomarker Detection Kits, where accuracy, reliability, and ease of use are converging to deliver exceptional results.
For each experiment, each ELISA plate needs to set the standard curve. The minimum detectable concentration of CEA-C004 is less than 3.0 pg/mL.
Three human serum samples with high concentrations of IL-8 were diluted 1:2, 1:4, 1:8, 1:16, 1:32 with Dilution Buffer to produce samples with values within the dynamic range and then assayed. On average, 103.12% of IL-8 was detected from serum samples.
Ten replicates of each of five samples containing different IL-8 concentrations were tested in one assay , Intra-Assay Precision CV<10%.
Five samples containing different concentrations of IL-8 were tested in three independent assays , Inter-Assay Precision CV<15%.
Recombinant IL-8 was spiked into 5 human serum samples, and then analyzed. On average, 97.54% of IL-8 was recovered from serum samples.
Recombinant IL-8 was spiked into cell supernatant sample, and then analyzed. On average, 98.87% of IL-8 was recovered from serum samples.
Bilirubin (simulated jaundice) concentration should be less than 20mg/dL, hemoglobin (simulated hemolysis) concentration should not be higher than 3500mg/dL, triglyceride (simulated lipemia) concentration may not be higher than 2.0g/L, Heparin concentration should be less than 40U/mL, EDTA concentration should be less than 4mg/mL, and Sodium citrate concentration may not be higher than 40mg/mL, it does not affect the detection result.
ID | Components | Size |
CEA004-C01 | Pre-coated Anti-IL-8 Antibody Microplate | 1 plate |
CEA004-C02 | IL-8 Calibrator | 20 μg×2 |
CEA004-C03 | Biotin-Anti-IL-8 Antibody Concentrated Solution | 100 μL |
CEA004-C04 | Biotin Antibody Dilution Buffer | 8 mL |
CEA004-C05 | IL-8 Streptavidin-HRP Concentrated Solution | 0.5 mL |
CEA004-C06 | Streptavidin-HRP Dilution Buffer | 15 mL |
CEA004-C07 | 20× Washing Buffer | 50 mL |
CEA004-C08 | Sample Dilution Buffer | 15 mL×2 |
CEA004-C09 | Substrate Solution | 12 mL |
CEA004-C10 | Stop Solution | 6 mL |
Price(USD) : $549.00
Price(USD) :
Price(USD) :
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Mouse monoclonal antibody against human interleukin-8 cream | Approved | Dalian Asia Space Pharmaceutical Co Ltd, Dongguan Hongyuan Yishi Biotechnology Pharmaceutical Co Ltd | 恩博克 | Mainland China | Eczema; Psoriasis | Dalian Asia Space Pharmaceutical Co Ltd | 2001-04-10 | Psoriasis; Eczema | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
AC-701 | AC-701 | Phase 2 Clinical | Twi Pharmaceuticals Inc | Rosacea; Exanthema | Details |
Ensereptide | PXL-01 | Phase 3 Clinical | Promore Pharma | Post-surgical adhesions; Cicatrix | Details |
HuMax-IL8 | MDX-018; BMS-986253 | Phase 2 Clinical | Medarex, Genmab A/S, Bristol-Myers Squibb Company | Solid tumours; Hematologic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Prostatic Neoplasms; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung | Details |
This web search service is supported by Google Inc.